About PolycapTM

For Prevention of Cardiovascular disease


The World Health Organization (WHO) had proposed the cardiovascular polypill more than a decade ago as a ‘best buy’ intervention for secondary prevention, and a simple, cost-effective strategy to reduce the evidence implementation gap and as an instrument to improve the prescription, accessibility, adherence and cost of secondary CVD prevention.

The concept of a polypill, composed of a combination of medications that are known to effectively treat CVD, has been proposed as a simple, cost effective and innovative public health strategy to combat the CVD epidemic on a global scale. Several studies have shown the polypill to be well tolerated and superior in terms of adherence to standard of care.

Polypills include guideline-recommended treatments for secondary prevention, such as BP-lowering, cholesterol-lowering and antiplatelet drugs. Polypill strategies have been shown to be effective.

Safe and cost-effective in terms of increasing drug adherence and improving risk factor profiles. As a result of these findings, the use of polypills was included in the 2016 European Guidelines on CVD prevention in clinical practice.

A cardiovascular Polypill could be one potential solution to poor compliance by simplifying the treatment regimen.

The POLYCAP is fixed-dose combination of three blood-pressure-lowering drugs, Atenolol 50 mg, Ramipril 5 mg, Hydrochlorothiazide 12.5 mg, along with a lipid lowering drug, Simvastatin 20mg and an anti-platelet agent, Aspirin 100mg.

Guidelines for the management of arterial hypertension 2013 ESH/ESC guidelines.

  • TIPS study has shown that, when combined into the Polypill, different agents maintain all or most their expected effects.
  • The treatment simplification associated with this approach may only be considered, if the need for each Polypill component has been previously established.

European Guidelines on cardiovascular disease prevention in clinical practice 2012 guidelines:

  • Reducing dosage demands in persons at high CVD risk may result in the prescription of combination pharmacotherapy, the ‘Polypill’.
  • Recently, a randomized phase II trial in middle-aged individuals without CVD demonstrated that the ‘Polycap’ formulation could conveniently reduce multiple risk factors.

WHO Expert committee recommendation:

  • Fixed dose combination therapy including aspirin, beta-blockers, ACE-inhibitors, and statins have been advocated by the WHO for CVD.

Recommendation from ELITE organizations:

  • Reducing dosage demands is the most effective single approach toward enhancing adherence.
  • Fixed dose combination therapy (POLYCAP) reduces dosage demands.

Polypill in Textbook :

Harrison's Principles of Internal Medicine 17th edition Chapter: e38, THE POLYPILL.

  • The concept of a Polypill to reduce the burden of CVD is attractive and seems to have great potential, especially in secondary and high-risk primary prevention.
  • Polypill would be applicable to the wider population, with greater safety.

Advantages of Polycap in CVD


Improved Delivery of Care

By avoiding complex algorithms to identify individuals for therapy, increasing the ease of prescribing, and avoiding multiple steps for dose titration of each drug, more at-risk individuals could be treated and blood pressure would be reduced more quickly and substantially.

A study of high-risk patients with ischemic heart disease (IHD) or diabetes mellitus showed that use of a cardioprotective bundle, a simplified regimen involving fixed doses of a generic Statin and ACE inhibitor/ARB, delivered with minimal physician visits, reduced hospitalizations for IHD or stroke within 1 year. Moreover, fixed-dose combination drugs are already widely used in hypertension and in other conditions such as AIDS and tuberculosis.


Improved Adherence

Individuals would need to take only one instead of several pills per day for CVD prevention, which may enhance adherence.

Reduced Cost

Costs of a Polypill using generic components are likely to be much lower than the total costs of individual drugs.

Product Journey

The International PolycapTM Study

TIPS - 1


View Report

TIPS - 2


View Report

TIPS - 3


View Report